Predicted susceptibility of etravirine in HIV patients experiencing virological failure secondary to non-nucleoside reverse transcriptase inhibitor resistance in Argentina.
PMID: 21592625
2011
Enfermedades infecciosas y microbiologia clinica
Abstract: ETR-RAMs were defined as V90I, A98G, L100I, K101E/H/P, V106I, E138A, V179D/F/T, Y181C/I/V, G190A/S, and M230L, and were analyzed according to the weighted mutation score to predict susceptibility (Vingerhoets 2008).
HIV-1 drug resistance at antiretroviral treatment initiation in children previously exposed to single-dose nevirapine.
Result: NNRTI minor mutations were also detected, specifically E138A (n=20), V179D (n=7), V90I (n=3) and A98G (n=1), as well as the NNRTI-associated polymorphisms K101Q/T (n=3), E138G/S (n=3), V179A (n=2), H221Y (n=2) and L234P (n=1).
Effect of mutations at position E138 in HIV-1 reverse transcriptase on phenotypic susceptibility and virologic response to etravirine.
PMID: 21637112
2011
Journal of acquired immune deficiency syndromes (1999)
Abstract: At baseline, only E138A and Q were found at 3.0% and 2.5%, respectively.
Abstract: Site-directed mutants harboring E138A/G/K/Q/R or S showed etravirine fold change values of 2.9, 2.4, 2.6, 3.0, 3.6, and 2.8, respectively.
Abstract: Virologic response (less than 50 copies/mL) was observed in six of 12 and eight of 10 patients with E138A and E138Q, respectively.
Selection of HIV resistance associated with antiretroviral therapy initiated due to pregnancy and suspended postpartum.
PMID: 21765365
2011
Journal of acquired immune deficiency syndromes (1999)
Result: Several mutations associated with drug resistance that were not evaluated by OLA were detected by consensus sequencing, including M41L, V118I, E138A, and L210W.
Prevalence and resistance mutations of non-B HIV-1 subtypes among immigrants in Southern Spain along the decade 2000-2010.
Method: The only additions to this list since that time are K101H, E138A, and M230L, all etravirine-associated changes and K101P associated with resistance to NVP, EFV and etravirine.
Factors associated with virological response to etravirine in nonnucleoside reverse transcriptase inhibitor-experienced HIV-1-infected patients.
PMID: 19901096
2010
Antimicrobial agents and chemotherapy
Abstract: Mutations Y181V and E138A were independently associated with poor VR, whereas no effect of the Y181C on VR was observed.
Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naive patients infected with non-B HIV-1 subtypes.
PMID: 20008779
2010
Antimicrobial agents and chemotherapy
Abstract: Three new mutation profiles (E138A and V179I, Y181C and H221Y, and V90I and Y181C) showing decreased ETR phenotypic susceptibility were identified.
Antiretroviral drug resistance mutations in the reverse transcriptase gene of HIV-1 isolates from Northern Indian patients: a follow-up study.
Abstract: Phylogenetic analysis revealed two new recombinant forms, CRF_CH and CRF_CK, and an accessory non-nucleoside reverse transcriptase inhibitor mutation E138A, not previously reported from India.
The HIV-1 integrase mutations Y143C/R are an alternative pathway for resistance to Raltegravir and impact the enzyme functions.
Method: We followed-up the 50 mutations of resistance present at 32 positions: associated with in vitro or in vivo resistance to HIV-1 integrase inhibitors: H51Y, T66I/A/K, V72I, L74I/A/M, E92Q, T97A, T112I, F121Y, T125K, A128T, E138 K/A/D, G140R/C/H, Y143C/H/R, Q146K/P, S147G, Q148K/R/H, V151I,
ViMRT
HIV mutation literature information.
PMID: 
2011
Enfermedades infecciosas y microbiologia clinica
